BioWorld International Correspondent
DUBLIN, Ireland - Billam plc, a London-based investment vehicle, has orchestrated a three-way merger between early stage portfolio companies and has invested [pounds sterling]1.4 million (US$2.2 million) in the enlarged entity.
The transaction unites Cork, Ireland-based Eirx Therapeutics Ltd., which is focused on apoptosis target discovery and drug development, with Physiomics plc, an in silico systems biology specialist based at Oxford University, and CuDos Ltd., a company based at Nottingham Trent University in the UK that is developing non-animal in vitro toxicity testing methods.
Sam Holtzman, co-founder of Entelos …
No comments:
Post a Comment